Abbott Laboratories reports $44.33 billion revenue for fiscal year ended December 31, 2025, up 5.7%

ยท ABT

Abbott Laboratories reported revenue of $44.33 billion for the year ended December 31, 2025, an increase of 5.7% from the previous year ($41.95 billion).

For the same period it posted net income of $6.52 billion, down 51.3%, or $3.72 per diluted share (7.64 a year earlier).

That is a net margin of 14.7%.

On Sanad's AAOIFI Standard 21 screen, Abbott Laboratories is currently compliant: interest-bearing debt is 17.2% of market capitalisation (limit 30%), and impure income is 0.7% of revenue (limit 5%).

Source: 10-K filed with the U.S. Securities and Exchange Commission on February 20, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Abbott Laboratories news